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Abstract
Misfolding of the cellular prion protein (PrPC) into the scrapie prion protein (PrPSc) results in
progressive, fatal, transmissible neurodegenerative conditions termed prion diseases.
Experimental and epidemiological evidence point toward a protracted, clinically silent phase
in prion diseases, yet there is no diagnostic test capable of identifying asymptomatic individ-
uals incubating prions. In an effort to identify early biomarkers of prion diseases, we have
compared global transcriptional profiles in brains from pre-symptomatic prion-infected mice
and controls. We identified Cst7, which encodes cystatin F, as the most strongly upregu-
lated transcript in this model. Early and robust upregulation of Cst7 mRNA levels and of its
cognate protein was validated in additional mouse models of prion disease. Surprisingly, we
found no significant increase in cystatin F levels in both cerebrospinal fluid or brain paren-
chyma of patients with Creutzfeldt-Jakob disease compared to Alzheimer’s disease or non-
demented controls. Our results validate cystatin F as a useful biomarker of early pathogene-
sis in experimental models of prion disease, and point to unexpected species-specific differ-
ences in the transcriptional responses to prion infections.
Introduction
Prion diseases or transmissible spongiform encephalopathies are rare, late-onset, rapidly pro-
gressing and fatal infectious neurodegenerative disorders [1]. They include sporadic, genetic,
variant or iatrogenic Creutzfeldt-Jakob disease (CJD) in humans, ovine scrapie, bovine spongi-
form encephalopathy, and chronic wasting disease of deer and elk [1]. The etiologic agent is
termed prion and consists of the scrapie prion protein (PrPSc), a misfolded, aggregated, often
partially protease-resistant conformer of the cellular prion protein (PrPC) [2]. PrPSc is postu-
lated to exist in different conformations, corresponding to different prion strains, which differ
in their biochemical properties, and cause different forms of the disease in susceptible host
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species [3]. Misfolding of PrPC into PrPSc and accumulation of PrPSc aggregates within the
central nervous system (CNS) result in progressive neuronal loss and pathognomonic spongi-
form vacuolation, accompanied by intense astro- and microgliosis [4].
Neuroimaging and neuro-electrophysiological tests, analysis of 14-3-3 protein and other
surrogate biomarkers of CNS damage in the cerebrospinal fluid (CSF) and, more recently, the
demonstration of PrPSc seeding activity in CSF or nasal brushings, can support the diagnosis
of prion disease in the presence of a consistent clinical picture[5]. However, a definitive diag-
nosis requires the demonstration of PrPSc in brain tissue, most often performed post-mortem
with immunohistochemical-based techniques [5].
Experimental transmission, as well as acquired and iatrogenic cases of prion disease after
known exposure to prions, indicate that prion infection undergoes a long incubation before its
clinical onset [1]. Identification of patients with prion disease during the pre-clinical stage
could be instrumental in minimizing the risk of iatrogenic diseases (for example by deferral of
blood donors), and is a precondition to early intervention before the establishment of more
advanced neurodegeneration once effective therapies will become available. Disappointingly,
the development of validated diagnostic tests to identify pre-symptomatic patients with prion
disease still remains an unmet medical need.
In an effort to identify novel biomarkers of prion diseases, we performed a global, microar-
ray-based transcriptomic analysis in brains of pre-symptomatic, prion-infected mice [6]. This
led to the identification of the serine/cysteine protease inhibitor Serpina3n as an early upregu-
lated transcript during prion disease, and of urinary levels of its human homologue, α1-antic-
himotrypsin as a surrogate biomarker of prion infection [6]. In the present study, we have re-
analyzed this microarray dataset using alternative computational methods to uncover addi-
tional candidate biomarkers.
Materials and methods
Ethical statement
Animal care and experimental protocols were in accordance with the “Swiss Ethical Principles
and Guidelines for Experiments on Animals” and with the Swiss Animal Protection Law, and
approved by the Veterinary office of the Canton Zurich (permits 85/2003, 171/2004, 30/2005,
41/2012 and 90/2013). All efforts were made to minimise animal discomfort and suffering.
All human tissue samples used in this project were irreversibly anonymized and collected
before the year 2005. Approval by an Institutional Review Board is not required for the use of
irreversibly anonymized samples collected before the approval of the Swiss Medical-ethical
guidelines and recommendations (Senate of the Swiss Academy of Medical Sciences, Basel,
Switzerland, May 23rd 2006). The study using human CSF was approved by the Swiss Ethics
Committees of Canton Zurich (KEK-ZH-Nr. 2012–0376, Amendment dt. 05.07.2014).
Patient populations
Cohort 1. This cohort comprised CSF samples from cases with different neuroinfectious,
neuroinflammatory and neurodegenerative conditions. Leftovers from diagnostic CSF samples
were obtained from the biobank of the Department of Neurology, University Hospital Zurich.
Clinical data concerning diagnosis, gender, date of birth/death and lumbar puncture (LP)
were collected from medical charts and autopsy reports obtained from the hospital’s databases
PathoPRO and KISIM.
After the performance of desired diagnostic tests, CSF samples were spun down at 3000
rpm for 10 min, aliquoted and since then stored at -80˚ C.
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Cohort 2. This cohort comprised CSF samples from cases with autopsy-proven, definitive
Creutzfeldt-Jakob disease or Alzheimer’s disease, as well as cases with clinically diagnosed Alz-
heimer’s disease and from non-demented, control subjects.
Leftovers from diagnostic CSF samples from subjects with autopsy-proven, definitive Creutz-
feldt-Jakob disease (Def CJD, n = 39) or Alzheimer’s disease (Def AD, n = 11) were obtained from
the CSF biobank of the Swiss Referral Center for Prion Diseases (Nationales Referenzzentrum fu¨r
Prionenerkrankungen, NRPE, located at the Institute of Neuropathology, University Hospital
Zurich). The NRPE is in charge of the registration and surveillance of human transmissible spon-
giform encephalopathies in Switzerland. It provides, inter alia, p14-3-3 detection in CSF and
autopsies of possible or probable CJD patients from all over the country. CSF samples from the
NRPE-CSF biobank were sent ideally on dry ice from corresponding hospitals for p14-3-3 detec-
tion, temporarily kept at -20˚C awaiting Western blot analysis and were finally stored at -80˚ C.
Definitive diagnosis of Creutzfeldt-Jakob disease was made by a board certified neuropathol-
ogist, according to current guidelines after histopathological examination and the detection of
proteinase K resistant PrPsc in brain homogenates by Western blot analysis. Neuropathologic
assessment of Alzheimer type brain pathology was made according to the NIA/AA criteria [7].
For all NRPE cases, date of CSF draw, date of death and autopsy, histopathological report and
p14-3-3 results were available. Samples obtained from consecutive cases evaluated between
2004 and 2014 were included in this cohort. Cases with insufficient CSF leftover or with macro-
scopically haemorrhagic CSF (14 DEF CJD and 2 Def AD) were excluded from the study.
Leftovers from diagnostic CSF samples from subjects with clinically diagnosed Alzheimer’s
disease (Clin AD, n = 26) and from non-demented, control subjects (Controls, n = 24) were
obtained from the biobank of the Department of Neurology, University Hospital Zurich.
The clinical history of Alzheimer’s disease cases was extensively assessed and diagnosed
according to strictly applied diagnostic criteria. Patients underwent a cranial MRI scan (all),
neuropsychological evaluation (all), EEG (n = 22), Mini Mental Status (n = 24), CSF testing (all,
n = 11 with neurodegenerative markers such as p-tau and amyloid β). Twenty-five patients had
at least one additional follow up evaluation at the Clinic of Neurology after CSF withdrawal,
with the clinical picture being still compatible with a diagnosis of AD. In three cases the clinical
history was compatible with a diagnosis of mixed dementia caused by the coexistence of neuro-
degenerative and vascular changes. The group of clin AD was matched to the def AD and def
CJD groups in terms of patients’ age and gender and duration of sample storage.
The non-demented, control group (controls, n = 24) was composed of patients who under-
went clinical examination including lumbar puncture during the work-up of one of the follow-
ing symptoms: headache, vertigo, sleep disorder. Fourteen patients underwent a cranial MRI
showing no pathological changes. All patients received at least two clinical evaluations at dif-
ferent time points and no other neurological complaints including signs of cognitive
impairment or neurodegeneration were reported. The control group was matched to the oth-
ers based on the gender distribution and on the duration of sample storage.
Cohort 3. Archival brain tissue from patients with autopsy-proven, definitive Creutzfeldt-
Jakob disease (n = 11) or Alzheimer’s disease (n = 8) were obtained from the autopsy biobank
of the NRPE at the Institute of Neuropathology, University Hospital Zurich.
Mice
C57BL/6J male mice were purchased from Charles River. Mice were kept in a conventional
hygienic-grade facility, housed in groups of 3–5 in type IIL cages under a 12 h light/dark cycle
(light from 7 am to 7 pm) at 22±1˚C, with unrestricted access to sterilized food (Kliba No.
3340, Provimi Kliba, Kaiseraugst, Switzerland) and water.
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Prion inoculation. Mice were anesthetized with isofluorane and injected in the right
hemisphere with 30 μl of 0.1% of RML6 (passage 6 of Rocky Mountain Laboratory strain
mouse-adapted scrapie prions) or of 0.1% of non-infectious brain homogenate (NBH) from
CD-1 mice as control [8]. Mice were monitored three times per week in the absence of any
clinical sign of disease and every day after clinical onset. Clinical assessment and scoring were
performed as previously described [9] with minor modifications (S1 Table). Actions were
taken to minimize animal distress and suffering (S1 Table). Prion-infected mice were sacri-
ficed at 27, 56, 82, 110, 123 and 137 days post-inoculation (dpi) or when they reached the ter-
minal stage of prion disease at ca. 176 dpi. One additional group of control mice injected with
NBH was sacrificed one week after the last prion-injected mouse reached the terminal stage, at
192 dpi. Euthanasia was performed through transcardial perfusion with PBS after deep anes-
thesia with ketamine and xylazine (N-(2,6-Dimethylphenyl)-5,6-dihydro-4H-1,3-thiazin-
2-amine). Brain areas were dissected, snap frozen and kept at -80˚C until further processing.
Archival murine CNS samples from mice inoculated with RML and 22L rodent-adapted scra-
pie prions and control NBH-injected mice from previously published studies [6,8,10] were
analyzed.
Experimental autoimmune encephalitis. Experimental autoimmune encephalitis was
induced in 13–16 week old C57BL/6 mice through subcutaneous administration of 200 μg of
MOG35-55 peptide (MEVGWYRSPFSRVVHLYRNGK; Neosystem, Strasbourg, France) emul-
sified in complete Freund’s adjuvant (CFA) supplemented with 4 mg/ml Mycobacterium
tuberculosis (DIFCO, Detroit, MI, USA), as previously described [11]. Mice received intraperi-
toneal injections with 200 ng pertussis toxin (Sigma, Switzerland) at the time of immunization
and 48 hours later. Control mice received an identical regimen with the exception of MOG35-
55 peptide. Clinical assessment and scoring were performed as previously described [11] and
actions were taken to minimize animal distress and suffering (S2 Table). Mice with experimen-
tal autoimmune encephalitis and control mice were sacrificed in parallel.
Genetically modified mice used in this study are listed in Table 1.
Reverse transcription and polymerase chain reaction
Total RNA was isolated using Trizol (Invitrogen AG, Switzerland) or the RNeasy Universal Plus
Mini kit (Qiagen). Prior to cDNA synthesis, residual genomic DNA was removed by the DNA
free-kit (Ambion, USA) or using the gDNA Wipeout buffer (Qiagen). cDNA was synthesized
using the bulk first strand cDNA synthesis kit and Not I-(dT)18 as primer (Amersham Biosci-
ences Europe GmbH, Germany) or with Quantiscript Reverse Transcriptase (Qiagen). Control
reactions omitting the reverse transcriptase enzyme were performed to verify successful removal
of genomic DNA. All these procedures were performed according to the manufacturers’ proto-
cols. Extracted RNA was analysed using a ND-1000 Spectrophotometer (NanoDrop).
Primer pairs were designed using Primer3 software (http://frodo.wi.mit.edu/cgi-bin/
primer3/primer3_www.cgi) or using NCBI primer blast (http://www.ncbi.nlm.nih.gov/tools/
primer-blast/) or derived from [12].
Table 1. Genetically modified mice used in this study.
Line (abbreviation) Genetic modification Description of mice used Ref.
PrnpΔF (ΔF) Transgenic mice expressing a truncated PrPC (32–134) on a
B6129-PrnpZrchI/ZrchI background
Adult mice with signs of neurodegeneration [31]
B6-Tg/Thy1APP23Sdz
(APP23)
Transgenic mice overexpressing the human APP with the
Swedish double mutation at 670/671 (KM!NL)
1.5 year-old mice with histologic evidence of
astrogliosis, microgliosis and amyloid β plaque
[32]
C57BL/6J-PrnpZH3/ZH3
(ZH3)
Co-isogenic C57BL/6J mice lacking the cellular prion protein. Adult mice [18]
doi:10.1371/journal.pone.0171923.t001
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For amplification we used the SYBR Green PCR Master Mix (Qiagen) or the Fast Start
SYBR Green Master Mix (Roche) with 0.3–1 uM of each forward and reverse primers for the
target of interest and cDNA (or no reverse transcriptase sample or water, as controls) as
template.
The reaction was run on an ABI PRISM 7700 Sequence Detection System (Applied Biosys-
tems) or on a ViiA 7 Real-Time PCR System (Life Technology) using default cycle conditions
followed by a melting curve analysis. Samples were tested in technical triplicates. Expression of
a subset of transcripts identified by microarray as upregulated during prion disease (which
also included Cst7) was measured in mouse brain and normalized to Actb levels. Expression of
Cst7 in different mouse organs was normalized by geNorm [13] to the levels of the following
normalization genes: Gapdh, Eif2a, Utp6c, Hprt1.
Northern blotting
Total RNA was isolated using Trizol (Invitrogen AG, Switzerland) according to standard pro-
cedures. Northern blotting was performed exactly as previously described[6]. Northern blot-
ting for Cst7 was performed in parallel to Northern blotting for Serpina3n, Gfap and Rn18s as
reported in [6] and hence blots for Serpina3n, Gfap and Rn18s are reproduced from [6].
Murine cDNAs for derivation of Cst7 probe was obtained from Open Biosystems (www.
openbiosystems.com), accession number AA089317.
Uniform adjustment of contrast and levels on the acquired images and subsequent crop-
ping were performed using Adobe Photoshop. Unprocessed Northern and Western blot
images are provided in S1 File.
RNA sequencing
Data on Cst7 mRNA expression levels in different cell types of the mouse brain were retrieved
from the RNA-sequencing-based transcriptome database for mouse brain cortex cells [14].
Data on CST7 mRNA expression levels in different cell types of the human brain were re-
trieved from the RNA-sequencing-based transcriptome database for human brain cortex cells
[15]. Data on Cst7 mRNA expression levels during microglia development and upon LPS stim-
ulation were retrieved from an RNA-sequencing-based transcriptome database for mouse
microglia cells [16]. RNA sequencing on hippocampi and cerebella of prion-inoculated and
control mice was performed essentially as described previously [17,18].
Antibody generation
Mouse monoclonal antibodies F010 and C067 against cystatin F were generated using mam-
malian cell display as previously described [19] with modifications. BALB/c mice were weekly
immunized with his-tagged human recombinant cystatin F conjugated to Qβ virus-like parti-
cle (VPLs) [19] in alum four times. Splenocytes from immunized mice were harvested and
stained with: FITC-labelled anti-mouse IgM/D, CD3, CD11c/b, CD4 and Gr-1; Qβ-bound
human cystatin F, anti-Qβ serum (rabbit) and PE labelled anti-rabbit IgG; PE-TexasRed
labelled anti-mouse CD19; Alexa 647 nm-labelled Qβ-VPLs (Cytos Biotechnology). Cystatin
F-specific B cells (cystatin F/CD19 positive, Qβ-VPLs/IgM-/IgD-/CD3-/CD11c/b-/CD4-/Gr-
1-negative) were sorted on a FACS Vantage SE flow cytometer (Becton Dickinson). Total
RNA was isolated from Cystatin F-specific B cells and used to generate a Sindbis virus-based
scFv library [19,20]. BHK cells were infected with the Sindbis virus-based single chain frag-
ment variable (scFv) library and stained with Qβ-conjugated human cystatin F, anti-Qβ serum
(rabbit) and PE labelled anti-rabbit IgG and a rabbit anti-sindbis virus serum and Cy5-labelled
anti-rabbit IgG (Cytos Biotechnology), in the presence of propidium iodide. Infected BHK
Cystatin F is a biomarker of prion pathogenesis in mice
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cells displaying cystatin F-specific scFv were individually sorted on 24-well plates containing
BHK feeder cells. At least 48 h after sorting/plating, cells from wells with signs of infection
were tested by flow cytometry for expression of cystatin F-binding scFv to identify viral clones
encoding cystatin F-specific scFv. Fusion single chain fragment variable/fragment crystal-
lizable (scFv-Fc) proteins were generated as previously described [19] and tested for binding to
human recombinant cystatin F (Cytos Biotechnology) in ELISA assays using standard proce-
dures. For expression as mouse IgG2aκ monoclonal antibodies, the heavy chain variable
region (HCVR) and light chain variable region (LCVR) coding segments of the cystatin F-
binding scFv molecules were PCR amplified using the following primer pairs (5’!3’, Micro-
synth): HCVR forward: CGA GGT GCA GCT GCT CGA GTC TGG GGC TGA GCT; HVCR reverse;
GAC AGA TGG GCC CGT TGT TTT GGC TGA GGA GAC; LCVR forward: GAT ATT GAG CTC
ACC CAG TCT CAA AAA TTC ATG; LCVR reverse: GCC ACC AGA GGA TTT GAT ATC CAG
CTT GGT CCC.
Heavy chain and light chain encoding regions were cloned into a Epstein Barr Virus-based,
pCB15 episomal expression vector allowing co-expression of immunoglobulin heavy and light
chains under the cytomegalovirus promoter [19]. Expression vectors were transfected into
HEK293T cells using Lipofectamin Plus (Invitrogen) and antibodies were purified from cell
supernatants using protein A-Sepharose columns (GE healthcare).
Tissue processing for Western blotting and ELISA
Human brain tissues from the NRPE-autopsy bio-bank were snap frozen and stored at -80˚C.
Ten-twenty percent brain homogenates (w/vol) were prepared in 2% Sacrosyl (Sigma) and
PBS, using lysing matrix tubes (MP Bio) and a Precellys 24 (Bertin Technologies). Samples
were spun down to remove gross debris and supernatants were stored at -80˚ C until further
analysis.
Mice were deeply anesthetized with ketamine-xylazine, transcardially perfused with a solu-
tion of PBS containing heparin and dissected organs were snap frozen and kept at -80˚C until
further analysis. Ten percent (w/vol) homogenates were prepared in either RIPA buffer
(25mM Tris-HCl pH 7.6, 150mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS)
+ Complete Mini Protease Inhibitor Cocktail (Roche) or in PBS + sucrose 0.32 M (Sigma),
using Stainless Steel Beads 5 mm (Qiagen) and Tissue Lyser LT (Qiagen). Samples were spun
down to remove gross debris and supernatants were stored at -80˚ C until further analysis.
ELISA
Sandwich ELISA was performed on 96-well ELISA plates (F96 Cert. Maxisorp Nunc-immuno
plate) coated with 5 μg/mL of the monoclonal mouse anti-cystatin F antibody F010 in PBS
(pH = 7.2, Gibco). After overnight incubation, plates were washed 5 times with PBS supple-
mented with 0.1% (vol/vol) Tween-20 (PBST) using a 96-well plate washer (BioTek Instru-
ments, ELx405). Nonspecific binding sites were subsequently blocked with 5% (w/vol) fat-free
milk in PBST for 2h at room temperature. Recombinant cystatin F (AJ Roboscreen) was sub-
jected to 1:2 serial dilution in sample diluent buffer (1% w/vol fat-free milk in PBST) to gener-
ate a standard curve with the following concentrations: 1000, 500, 250, 125, 62.5, 31.25, 15.6,
7.8 pg/ml. Blocking buffer was removed and standards/samples were loaded in either dupli-
cates (undiluted CSF) or triplicates (cell lysates and tissue homogenates, diluted in sample dil-
uent buffer). Plates were incubated for 2h at 37˚C and washed 5 times. For detection of the
captured antigen, plates were incubated with 0.75 μg/ml of the biotinylated monoclonal mouse
anti-cystatin F antibody C067 for 1h at 37˚C, then washed 5 times. Avidin-horseradish-peroxi-
dase HRP (BD Pharmingen) diluted 1:1000 in sample diluent was loaded. After incubation of
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45 min at 37˚C plates were washed 5 times and developed with 3,3’,5,5’-tetramethylbenzidine
substrate solution (high sensitivity TMB, BioLegend), for 10 min at room temperature in the
dark. The reaction was stopped by adding stop solution, 0.18 M H2SO4. Plates were read at
wavelength of 450 nm on a Versamax SNB plate reader (Molecular Devices).
Standard curves were generated using a four-parameter logistic (4PL) equation to calculate
concentrations of unknown samples. Values of all 4 parameters were determined by SOFTmax
PRO software (Molecular Devices).
To assess matrix effects in the assay, recombinant human cystatin F (Cytos Biotechnology)
was spiked in pooled human CSF with the concentrations 1000, 500, 250, 125, 62.5, 31.25, 15.6
pg/ml and compared to the observed values with the expected protein levels diluted only in
sample diluent buffer. We obtained measured levels differing up to 22% with respect to nomi-
nal values in the range between 62.5 and 1000 pg/mL. Below 62.5 the discrepancy was larger,
possibly due to the presence of endogenous cystatin F in pooled human CSF used for spiking.
Macroscopically haemorrhagic CSF samples were excluded, as preliminary results indicated
extensively elevated cystatin F concentrations due to blood contamination.
Intra-assay variability was evaluated by spiking recombinant cystatin F into pooled human
CSF at the following concentrations: 500, 62.5, 7.8 pg/ml. Validation samples were measured
in 10 replicates. The coefficient of variation (%CV) was 2.5%, 6.2% and 10.5%, respectively.
To account for possible inter-assay variability, for measurements in mouse brain homoge-
nates from different experiments, cystatin F levels are normalized to levels in NBH-injected
control mice, whereas for measurements in human CSF samples 3 pre-defined CSF cases were
employed as internal calibrators to pool data for the evaluation of cystatin F levels in CSF sam-
ples from cohort 2.
Western blotting
Total protein concentration of tissue homogenates was measured using the BCA Protein
Assay (Pierce), according to the manufacturer’s instructions. For proteinase K (PK) digestion,
PK (100 μg/ml, pH = 7, Roche) was added aiming for a final concentration of 25 μg/ml and
incubated at 37˚C for 30 min; the reaction was stopped by adding NuPAGE 4xLDS sample
buffer (Invitrogen) with β-mercaptoethanol (Sigma-Aldrich) and boiling at 95˚C for 10 min.
Separation was performed on a NuPAGE 12% Bis-Tris gel (Invitrogen) and transferred onto a
Protran Nitrocellulose Transfer Membrane (Whatman) using the NuPAGE Gel Electrophore-
sis System (Invitrogen) or the Mini Trans-Blot cell System (Bio-Rad). After blotting, the mem-
brane was washed once with PBS supplemented with 0.1% (vol/vol) Tween-20 (PBST),
blocked with 5% (w/vol) fat-free milk in PBST and decorated with mouse anti-PrP POM1 [21]
(300 ng/ml in 1% (w/vol) fat-free milk in PBST) overnight at 4˚C. After washing, the mem-
brane was probed with rabbit anti-mouse IgG2a antibody (1:10’000 dilution, Zymed). Blots
were developed using Luminata Western HRP Substrates (Millipore) and visualized using
either a Stella (Raytest) or LAS-3000 (Fujifilm) luminescent image analyzer. After initial image
acquisition, membranes were washed, reprobed with mouse anti-actin monoclonal antibody
(1:10’000 dilution, Millipore) and the same procedure was followed for acquisition of the actin
signal. Uniform adjustment of contrast and levels on the acquired images and subsequent
cropping were performed using Adobe Photoshop. Unprocessed Western blot images are pro-
vided in S1 File.
Immunohistochemistry
Tissues were fixed in formalin, treated with concentrated formic acid to inactivate prions and
embedded in paraffin. Tissue sections were subjected to deparaffinization through graded
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alcohols and heat-induced antigen retrieval in EDTA-based buffers. Stainings were performed
on a NEXES immunohistochemistry robot (Ventana instruments) or on a BOND-III robot
(Leica) using the following antibodies: 1:200 dilution of 3F4 (stock concentration 2 mg/ml, puri-
fied in house) for PrP staining; 1:3000 dilution of 4G8 (Signet) for Aβ staining; 1:1000 dilution of
AT8 (Thermo Fisher Scientific) for staining of phosphorylated tau; 1:200 dilution of HPA040442
(Sigma) for cystatin F; 1:1000 dilution of rabbit anti-Iba1 (Wako). Immunoreactivity was visual-
ized using an IVIEW DAB Detection Kit (Ventana) or Bond Polymer Refine Detection Kit
(Leica). Haematoxylin and eosin staining was performed according to a standard protocol. For
image analysis and acquisition, slides were scanned with NanoZoomer and images were obtained
using the NanoZoomer Digital Pathology System (NDPview, Hamamatsu Photonics).
Statistical analysis
Microarray data from a previous study [6] were re-analyzed using the perfect match-mismatch
model-based expression analysis algorithm (www.dchip.org). Differentially expressed genes
were defined as having an absolute fold change1.3, a confidence interval >90% and Stu-
dent’s t test p value <0.05 when comparing expression values between RML-infected vs. NBH-
injected control mice.
Statistical analysis was performed using Graphpad Prism software and SPSS. Significance
between two groups was determined by unpaired Student’s t-test. Comparison between multi-
ple groups was assessed by One-way ANOVA followed by Bonferroni’s or Dunnet’s Multiple
Comparison Test or Fisher’s least significant difference (LSD) post-hoc test, as stated in corre-
sponding figure legends. P-values<0.05 were considered as statistically significant. For the sta-
tistical analysis, a normalizing log-transformation of murine Cst7 mRNA levels and of mouse
and human cystatin F values was applied. A multi-factorial analysis of co-variance (ANCOVA)
of the log-transformed analysis variable cystatin F was performed on the data from Cohort 2
using SPSS. Categorical ANCOVA factors were diagnosis group and sex; continuous covari-
ates were age of patient, age of CSF sample and total protein concentration. An additional
term was included in the ANCOVA model to account for a possible interaction between sex
and diagnosis.
Results
Microarray analysis of prion-infected mouse brains unveils Cst7 as a
candidate biomarker
We had previously performed a genome-wide, microarray-based transcriptomic analysis on
brains from C57BL/6J mice at 145 days after intraperitoneal injection with RML prions (or
non-infectious brain homogenate, NBH, as control) [6]. Under this experimental paradigm,
the onset of clinical signs occurs at around 180 dpi, whereas the terminal stage is achieved at
around 200 dpi in prion-inoculated mice. Microarray data were initially analyzed using the
perfect-match-only model-based expression analysis algorithm, which relies on hybridization
intensities of the perfect match probes, 25mers containing the canonical sequence for the cor-
responding transcripts. This approach allowed the identification of 77 differentially expressed
transcripts, including Serpina3n [6].
To identify additional transcripts differentially expressed in the early, pre-clinical phases of
experimental prion disease, we have re-analyzed this dataset. We have taken advantage of the
presence, within the employed microarray chip, of the mismatch probes. These are 25mer
probes containing a deliberate mutation at position 13 and as such designed to measure non-
specific or cross-hybridization [22,23]. We have therefore applied the perfect-match mismatch
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model-based expression analysis algorithm and focused on differentially expressed genes with
absolute fold change1.3, a confidence interval>90% and Student’s t test p value <0.05. By
applying these filters, we identified 278 differentially expressed probes, corresponding to 259
genes, of which 201 genes were upregulated and 58 genes were downregulated in the brain of
prion-infected vs. control mice (Fig 1A, S4 Table). Of note, the majority (78%) of these dif-
ferentially expressed probes were not previously identified when using the perfect-match only
algorithm. Remarkably, among the newly identified differentially expressed genes was Cst7,
which represented the gene undergoing the strongest modulation in brains of prion-infected
mice, with an upregulation of8.7 fold.
Cst7 encodes for cystatin F, a secreted type-II cysteine protease inhibitor mainly expressed
in immune cells [24–28]. The early and strong upregulation of Cst7 mRNA during prion dis-
ease, along with the fact that cystatin F can be secreted into the extra-cellular space, prompted
us to investigate the role of cystatin F as a possible surrogate biomarker in prion diseases.
Levels of Cst7 transcripts during prion pathogenesis
To validate the upregulation of Cst7 transcripts during prion disease identified with the micro-
array, we performed quantitative RT-PCR analysis in brains of prion-infected versus control
mice (the latter injected with NBH). We analyzed samples at 145 dpi, the same pre-symptom-
atic stage used for microarray analysis [6], and at 190 dpi, when prion-inoculated mice showed
signs of disease and were close to the terminal stage. We measured levels of Cst7, as well as lev-
els of 28 additional transcripts which were found, to different extent, as upregulated in prion-
infected mice by microarray analysis. Quantitative RT-PCR analysis confirmed the upregula-
tion of all investigated transcripts at both time points (Fig 1B). Compared to microarray analy-
sis, RT-PCR showed a higher magnitude of upregulation, which, in the case of Cst7, was >40
fold in brains of prion-infected versus control mice (Fig 1A and 1B).
We then investigated the temporal pattern of Cst7 transcription in the CNS after prion
infection, and its relationship to the accumulation of partially protease-K resistant PrP. North-
ern blotting indicated an initial upregulation of Cst7 transcripts already at 110 dpi (Fig 2A),
when PrPSc becomes detectable by Western blotting in whole brains of prion-infected mice
(S1 Fig). The PrPSc signal progressively increased over time (Fig 2A). Compared to Serpina3n
and to Gfap, a marker of astrogliosis typically associated to prion disease, Cst7 mRNA upregu-
lation occurred earlier during prion disease (Fig 2A).
We next analyzed the course of Cst7 upregulation in selected areas of the CNS. Cst7 tran-
scripts were found to be upregulated in prion-infected spinal cords at 100 dpi (Fig 2B). By 140
dpi Cst7 mRNA levels were further increased in spinal cord and Cst7 upregulation became evi-
dent also in cerebellum and in cerebral cortex (Fig 2B). Again, Cst7 mRNA upregulation
occurred earlier with respect to Serpina3n and Gfap mRNA levels (Fig 2B).
We then used RNA sequencing to assess the number of Cst7 mRNA transcripts in the hip-
pocampi and cerebella of mice at various time points after intracerebral injection with either
RML prions or NBH (as control). In the hippocampus, Cst7 showed a trend toward upregula-
tion at 110 and 123 dpi (3 fold and 10 fold, respectively), which reached statistical signifi-
cance at 137 dpi (79 fold, p<0.05, One-way ANOVA, Dunnett’s Multiple Comparison Test)
and at the terminal stage of disease (168 fold, p<0.001, One-way ANOVA, Dunnett’s Multiple
Comparison Test; Fig 2C, S5 Table). At these two time points, the increase of Cst7 transcripts
was significantly larger than that of Serpina3n and Gfap (for both time points p<0.0001, Two-
way ANOVA, Bonferroni’s Multiple Comparison Test).
In the cerebellum, Cst7 was significantly upregulated at 110 dpi (8 fold, p<0.05, One-way
ANOVA, Dunnett’s Multiple Comparison Test), as well as at the terminal stage (251 fold,
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p<0.001, One-way ANOVA, Dunnett’s Multiple Comparison Test) compared to NBH-
injected mice (Fig 2C, S5 Table). At the terminal stage, Cst7 upregulation was significantly
higher than that of Serpina3n and Gfap (p<0.0001, Two-way ANOVA, Bonferroni’s Multiple
Comparison Test). In summary, Cst7 mRNA upregulation occurred earlier and was larger
than that of Serpina3n and Gfap (Fig 2C). Collectively, these data indicate that in C57BL/6
mice intraperitoneally or intracerebrally inoculated with RML prions, early, progressive and
robust upregulation of Cst7 mRNA occurs throughout the disease course.
Levels of Cst7 mRNA in other neurologic conditions
To study the cellular pattern of Cst7 expression within the mouse brain, we interrogated the
RNA-sequencing-based transcriptome database for mouse brain cortex cells [14]. This analysis
revealed that Cst7 ranked at the 48th percentile of expression of all mouse genes and that
Cst7 transcripts were significantly enriched in microglia/macrophages as compared to other
cell types of the brain cortex (S2 Fig), in line with the notion that Cst7/Cystatin F is mainly
expressed in immune cells, including microglia [29,30]. Of interest, transcriptomic analysis of
different cell types of the human brain [15] showed that CST7 ranked t the 43rd percentile of
expression of all human genes and that CST7 transcripts are mainly detected in microglia/mac-
rophages and endothelial cells (S2 Fig). Next, we analysed Cst7 mRNA levels in mouse micro-
glial cells during development and after an immune challenge with lipopolysaccharides using
the RNA sequencing-based transcriptome database for mouse microglia cells[16]. This showed
that Cst7 mRNA levels are stable during microglia maturation, whereas they show a trend
toward increase upon exposure to lipopolysaccharides (S2 Fig).
In light of these data, we asked whether neurologic conditions with prominent neuroin-
flammation/microgliosis other than prion disease may result in the upregulation of Cst7
mRNA. Cst7 mRNA overexpression as assessed by Northern blotting was evident to different
extents in the brains of terminally sick ΔF mice expressing a toxic, truncated PrPC molecule
[31], in mice with experimental autoimmune encephalitis [11], a model of multiple sclerosis,
and in aged TgAPP23 mice overexpressing human APPSwe/V717I [32], a model for Alzheimer’s
disease (AD) (S2 Fig). This analysis showed that mild brain Cst7 overexpression occurs in
other mouse models of neurologic conditions with neuroinflammation/microgliosis.
Cystatin F protein levels during experimental prion pathogenesis
We next aimed at studying cystatin F protein levels in mouse models of prion diseases. In
naïve C57BL/6 mice, cystatin F levels oin spinal cord, cerebellum and forebrain were signifi-
cantly lower than in thymus, in line with RT-PCR data of Cst7 mRNA in the same organs
(S3 Fig).
Fig 1. Microarray analysis identifies Cst7 as the most upregulated transcript in RML inoculated mice. A Heatmap
showing relative expression of 251 differentially expressed genes (absolute fold change1.3, a confidence interval >90%
and Student’s t test p value <0.05) between RML prion-inoculated mice (RML, n = 3, A to C) and control mice injected with
non-infectious brain homogenates (NBH, n = 3, A to C). For each gene, relative expression is defined as the ratio between
the actual gene expression of each mouse and the average gene expression from all 6 analyzed mice (the latter set as 1,
black) and is reported as grades of blue (downregulation) or red (upregulation). Expression data were obtained through the
employment of the perfect match mismatch model-based expression analysis algorithm of microarray data previously
reported in [6]. The list of differentially expressed genes is reported in S4 Table. B Validation of the upregulation of 29
transcripts (including Cst7) in RML-inoculated mice (n = 3) compared to NBH-injected controls (n = 3). Bars (left y axis) depict
mean and standard deviation of transcript fold change expression between brains of RML-inoculated mice and NBH-injected
controls (after normalization to Actb levels) at 145 and 190 days post-inoculation (dpi), as assessed by RT-PCR. Red
diamonds (right y axis) depict transcript fold change expression between brains of RML-inoculated mice and NBH-injected
controls at 145 dpi as assessed by microarray.
doi:10.1371/journal.pone.0171923.g001
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However, compared to NBH-injected control mice, RML prion-inoculated, terminally-sick
mice showed significantly higher levels of brain cystatin F (Fig 3A and 3B). We also studied
cystatin F levels in brains of C57BL/6 mice at different time points after intracerebral challenge
with the 22L inoculum, another strain of rodent-adapted scrapie prions. Compared to NBH-
injected control mice, a trend toward increased cystatin F levels was evident in brains of 22L-
inoculated mice already at 60 dpi, and at 90 dpi this difference reached statistical significance
and was maintained throughout the disease course, until the terminal stage, which was reached
at around 150 dpi (Fig 3C). Also, immunohistochemical analysis showed an increase in cysta-
tin F protein expression in brains of terminally-sick, 22L-inoculated mice compared with
NBH-injected controls, with a diffuse pattern compatible with the fact that the protein can be
released in the extracellular space (Fig 3D).
Cystatin F protein levels in human Cerebrospinal Fluid (CSF) samples
To gain a first insight into cystatin F levels in neurologic conditions other than prion diseases,
we analyzed a first cohort of patients with several neurodegenerative and neuro-infectious/
inflammatory conditions. This cohort included patients with various forms of cognitive
impairment (mild cognitive impairment, late-onset Alzheimer’s disease and fronto-temporal
dementia n = 4), Parkinson’s disease (n = 2), bacterial and viral meningitis (n = 3 and 8,
respectively), limbic encephalitis (n = 3), multiple sclerosis (n = 6) and neuroborreliosis
(n = 3). Cystatin F was detected in all CSF samples, with the highest levels observed in samples
from the bacterial meningitis groups (S4 Fig, p<0.01 compared to dementia and to multiple
sclerosis, p<0.05 compared to encephalitis, one-way ANOVA followed by Bonferroni’s post-
hoc test).
We next explored the role of cystatin F as a potential biomarker for prion diseases. For this
purpose, we analyzed CSF samples from patients referred to the NRPE for 14-3-3 analysis
because of clinical suspicion of prion disease. Of these cases, we included only cases of
autopsy-confirmed Creutzfeldt-Jakob disease or Alzheimer’s disease, whereas non-prion
related diagnoses were excluded. Cases evaluated at the Neurology Department of the Univer-
sity of Zurich with available CSF samples and with a definitive autopsy-based diagnosis were
also included. This resulted in 11 cases of definitive Alzheimer’s disease (“Def AD”) and 39
cases of definitive CJD (“Def CJD”). In addition, we also included 26 cases of Alzheimer’s dis-
ease diagnosed clinically based on stringent criteria (“Clin AD”), which were matched to the
Def AD and Def CJD groups by patient age as well as gender, and sample age. We included 24
cases with no neurodegenerative condition (“Controls”), consisting of subjects undergoing
lumbar puncture during the diagnostic work-up for headache, vertigo, or sleep disorders. This
latter group was matched to the others based on the sample age.
Fig 2. Spatial and temporal pattern of Cst7 upregulation in the central nervous system during experimental prion
pathogenesis. A Northern hybridization analysis of Cst7 mRNA in whole brains of mice at different time points (from 100 to 190
days post-inoculation, dpi) after injection with either non-infectious brain homogenate (NBH) or RML prions. For comparison,
expression levels of Serpina3n and Gfap mRNA are also shown. Hybridization for Rn18s, encoding 18S rRNA, is performed for
normalization. Each lane denotes a pool of brain extracts from 3 mice. B Northern hybridization analysis of Cst7 mRNA in
selected areas of the central nervous system (cb: cerebellum; sc: spinal cord; ob: olfactory bulb; cx: cortex) at different time
points after injection with either NBH or RML prions. For comparison, expression levels of Serpina3n and Gfap mRNA are also
shown. Hybridization for Rn18s, encoding 18S rRNA, is performed for normalization. Each lane denotes a pool of brain extracts
from 3 mice. C Cst7, Serpina3n and Gfap mRNA levels in hippocampus (hp) and cerebellum (cb) of RML-inoculated mice (n = 3)
compared to NBH-injected controls (n = 3). Bars depict mean and standard deviation of transcript fold change expression
between brains of RML-inoculated mice and NBH-injected controls at different time points post-inoculation (expressed as week,
wk), or at the terminal stage (term), as assessed RNA-sequencing. Dashed line indicates equal levels between RML-inoculated
mice and NBH-injected controls (fold change of 1). Data concerning Serpina3n, Gfap, Rn18s and PK-resistant PrP from panels
A and B reproduced, in modified form [6].
doi:10.1371/journal.pone.0171923.g002
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No significant differences were observed in patient’s age and gender distribution as well as
CSF sample storage time among Def CJD, Def AD and, as a result of the matching process,
Clin AD (Fig 4A and 4B). Instead, subjects from the control group were significantly younger
compared to the other groups but also in this case CSF sample storage time was similar thanks
to the matching process (Fig 4A and 4B). For cases for which an autopsy was performed
(namely Def AD and Def CJD groups), the time between lumbar puncture and the exitus was
significantly shorter for the Def CJD group (p = 0.0051, Student’s t test), in line with the more
rapid clinical course [33,34].
The highest cystatin F CSF levels were found in the Def AD group and these values were sig-
nificantly different compared to levels in the Controls (p<0.05, one-way ANOVA followed by
Bonferroni’s Multiple Comparison test). Notably, no significant difference was seen between
Def CJD and Controls (p = 1, one-way ANOVA), Def CJD and Def AD (p = 0.054, one-way
ANOVA) and Def CJD and Clin AD (p = 0.3, one-way ANOVA). Analysis of covariance was
performed on the log-transformed cystatin F levels taking into account possible influences of
sex, patient’s age at the time of lumbar puncture and age of CSF sample. There was no associa-
tion between diagnosis or gender and cystatin F levels (p = 0.239, ANCOVA). However, pa-
tient’s age was associated with cystatin F levels (p = 0.007, ANCOVA). Further analysis
showed that only for the Def AD group cystatin F levels correlate with patient’s age (r = 0.667,
p = 0.025).
Within the Def CJD group, there was no significant difference of cystatin F levels between
PrP type 1 and type 2 cases [35] (p = 0.14, Student’s t test, Fig 4E), nor between patients with
14-3-3 positive and negative results (p = 0.19, Student’s t test, Fig 4F).
Collectively, these analyses indicate the lack of a significant increase of cystatin F levels in
CSF samples of Creutzfeldt-Jakob disease cases compared to clinically relevant controls.
Cystatin F protein levels in human brain samples
We next aimed at comparing cystatin F levels in the brain parenchyma of Creutzfeldt-Jakob
disease vs. Alzheimer’s disease patients. To this purpose, we examined a third cohort compris-
ing 11 and 8 autopsy-confirmed cases, respectively. We focused on frontal cortex, a brain area
commonly affected both by amyloid β pathology in Alzheimer’s disease and by partially PK-
resistant PrP in Creutzfeldt-Jakob disease, as well as on cerebellum, which is rarely involved by
amyloid β pathology in Alzheimer’s disease [7,36,37].
Cystatin F levels were not significantly different between patients with Creutzfeldt-Jakob
disease and Alzheimer’s disease, both sampled from the frontal cortex and cerebellum (Fig
5A), with linear regression analysis indicating a correlation of cystatin F levels in the two
regions of the same case (Fig 5B). Also, within each diagnostic group, no significant difference
was observed between cystatin F levels in the frontal cortex and in the cerebellum (Fig 5A).
Moreover, immunohistochemical analysis could not detect any cystatin F in the frontal cortex
Fig 3. Cst7/cystatin F brain expression during prion pathogenesis. A Western blotting analysis in brain extracts of terminally sick,
prion-infected mice (RML), and of mice injected with non-infectious brain homogenate (NBH), showing the amount of partially protease
K (PK)-resistant prion protein (PrP) (left panel). Identical protein extracts omitting proteinase K treatment were used for Western blotting
with an anti-PrP and anti-actin antibody to verify equivalent loading in each lane (right panel). ZH3 denotes brain from a C57BL/6J-
PrnpZH3/ZH3 mouse as control. Each lane denotes one mouse. B Cystatin F levels in brain extracts from the same mice depicted in A,
relative to levels in NBH-injected mice (set as 100%; ***, p<0.001, Student’s t test). C Cystatin F levels in brain extracts from mice
injected with either non-infectious brain homogenate (NBH) or 22L prions at different time points (dpi, days post-inoculation; term,
terminal prion disease, reached at approximately 150 pdi in this experiment), relative to levels in NBH-injected mice at 150 dpi (ns,
p>0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001, one-way ANOVA followed by Bonferroni’s Multiple Comparison test). D Histological
analysis of cystatin F expression in cerebella of 22L-inoculated mice at the terminal stage of the disease and the relative NBH-injected
controls. Three representative mice per each group are depicted. Scale bar: 100 μm.
doi:10.1371/journal.pone.0171923.g003
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of these patients with Creutzfeldt-Jakob disease and Alzheimer’s disease, despite the presence
of microgliosis as detected by Iba1 stainings (S5 Fig) and the presence of partially protease-
resistant PrP in the former and amyloid β deposits and neurofibrillary tangles in the latter (Fig
5C). Conversely, cystatin F was detectable, mainly in infiltrating cells, in cases of encephalitis,
as well as in other tissues known to express cystatin F such as bone marrow (Fig 5C). Collec-
tively, these data indicate similar levels of cystatin F levels in brain parenchyma of patients
with Creutzfeldt-Jakob disease and Alzheimer’s disease.
Discussion and conclusion
A global transcriptomic analysis has identified Cst7 as a highly upregulated transcript in the
brain of prion-inoculated mice in the preclinical stage of the disease. Further analyses validated
Fig 4. Cystatin F levels in cerebrospinal fluid from patients with Creutzfeldt-Jakob diseases, Alzheimer’s disease and controls. Cystatin F levels
were measured in patients with autopsy-confirmed definitive Creutzfeldt-Jakob disease (Def CJD) or Alzheimer’s disease (Def AD), clinically diagnosed
Alzheimer’s disease (Clin AD) and non-demented controls (Controls). A Age and gender distribution (****, p<0.0001 against all other categories, one-way
ANOVA followed by Bonferroni’s Multiple Comparison test). B Sample storage of archival cerebrospinal fluid (CSF). C Time interval between lumbar puncture
(LP) and exitus for deceased patients with autopsy-confirmed diagnosis of neurodegeneration (Def AD and Def CJD; **, p<0.01, Student’s t test). D Cystatin
F levels in CSF from all study subjects from cohort 2 (*, p<0.05, one-way ANOVA followed by Bonferroni’s Multiple Comparison test). E Sub-analysis of
cystatin F levels in CSF from Def CJD subjects according to the PrP type[35]. F Sub-analysis of cystatin F levels in CSF from Def CJD subjects according to
the results of p14-3-3 Western blotting analysis as performed at the time of CSF sample collection. In all panels: Dots: denote individual subjects; bars: mean;
error bars: standard deviation.
doi:10.1371/journal.pone.0171923.g004
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this finding, showing that Cst7 upregulation occurs early during prion pathogenesis, parallels
the appearance of partially PK-resistant PrP, and has a magnitude of change that is unmatched
by other examined prion-induced transcripts. Cst7 encodes cystatin F, which is mainly ex-
pressed by immune cells, with microglia being the main cellular source of Cst7 expression
within the brain. Importantly, upregulated Cst7 translated into higher cystatin F protein levels
in the brains of prion-inoculated mice. All these findings, together with the observation that
cystatin F can be secreted in the extracellular space and is found in biological fluids, formed
the rationale for investigating the possible role of cystatin F as a biomarker of prion diseases.
Microglial Cst7 can be induced by lipopolysaccharide challenge, and moderately increased
Cst7 levels were observed in different mouse models of neurodegenerative and neuroinflam-
matory conditions with microgliosis. Therefore, we first analyzed a cohort of CSF samples
from subjects with different neuro-infectious, -inflammatory and -degenerative diseases. Sig-
nificantly increased levels of cystatin F were observed in the CSF of patients diagnosed with
bacterial and viral meningitis. In light of the cellular origin of cystatin F, this observation possi-
bly reflects blood-brain-barrier leakage and associated CSF leucocytosis that is often observed
in the course of bacterial and viral meningitis [38,39]. The fact that infectious conditions of the
central nervous system are accompanied by significantly increased CSF cystatin F levels does
not necessarily represent a limitation, as in the vast majority of the cases these conditions are
not relevant in the differential diagnosis of CJD.
We next measured cystatin F levels in CSF samples from patients with rapidly progressive
dementia and autopsy-confirmed Creutzfeldt-Jakob or Alzheimer’s disease, as well as in
patients with clinically diagnosed Alzheimer’s disease and non-demented controls. Unexpect-
edly, we found no significant increase in CSF levels of cystatin F among Creutzfeldt-Jakob dis-
ease cases compared to all other diagnostic groups.
A certain degree of pre-analytical variation, especially in sample withdrawal, processing,
storage and shipping, may play a role as a confounding factor [40], since our work was a retro-
spective study mainly based on external CSF samples sent to our reference laboratory in the
context of the clinical work-up for suspected Creutzfeldt-Jakob disease. On the other hand, we
found no correlation between CSF sample age and cystatin F levels, and the measured total
protein levels were in line with the different diagnoses (data not shown). This finding essen-
tially excludes the likelihood of substantial protein degradation.
Metabolism, biodistribution and the half-life of cystatin F in different biological fluids, as
well as the contribution of blood-borne vs brain-borne cystatin F within the CSF remain
largely unknown. Taking these aspects into consideration, we analysed cystatin F levels in
autoptic brain tissue to elucidate whether there was any significant upregulation of this protein
in the brains of patients with Creutzfeldt-Jakob disease. Remarkably, no significant differences
were observed between Creutzfeldt-Jakob disease and Alzheimer’s disease brain tissue, in line
with the results in CSF samples.
Fig 5. Cystatin F levels in brains from patients with Creutzfeldt-Jakob disease and Alzheimer’s
disease. A Cystatin F levels in frontal cortex (FCx) and cerebellum (Cb) of patients with autopsy-confirmed
definitive Creutzfeldt-Jakob disease (Def CJD) or Alzheimer’s disease (Def AD). Dots: denote individual
subjects; bars: mean; error bars: standard deviation. B Correlation of cystatin F levels in the two regions of
each patient, denoted by a dot (R2 0.73 for Def AD and 0.83 for CJD, linear regression analysis). C Histologic
analysis of cystatin F expression in frontal cortex of the same cohort of patients. Regions with abundant
pathology, including amyloid β (Aβ) plaques and neurofibrillary tangles (Tau, further magnified in the inset) in
Alzheimer’s disease and spongiosis and partially protease resistant prion protein (PrP) in Creutzfeldt-Jakob
disease, from representative cases are depicted. Non-demented subjects were included as control (Ctrl).
Lower row, left: encephalitis, with cystatin F positive infiltrating cells (further magnified in the inset at center).
Lower row, right: bone marrow, with cystatin F positive cells (further magnified in the inset). Scale bar: 100 μm
(black) or 25 μm (blue).
doi:10.1371/journal.pone.0171923.g005
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Alternatively, brain-derived cystatin F may be preferentially retained or degraded within
brain parenchyma, without significantly diffusing into the CSF. Cystatin C belongs to the
cystatin type II super family–like cystatin F–and has amyloidogenic properties [41], and the
Leu68Gln variant (CST3 p.Leu94Gln) causes hereditary amyloidosis with cystatin C amyloid
deposition within the CNS [42,43]. Further, in vitro and in vivo studies in mice indicate that
cystatin C co-aggregates with amyloid β and thus inhibits oligomerization and fibril formation
in Alzheimer’s disease models [44,45]. Similarly, cystatin F could be sequestered by PrPSc
aggregates and accumulate in the brain instead of diffusing into the subarachnoid space and
hence no elevated concentrations would be detectable in the CSF. To test for this hypothesis,
we investigated cystatin F expression and distribution within brain tissue by immunohis-
tochemistry. This analysis failed to detect a significant accumulation of cystatin F in brain
areas with prominent PrPSc aggregates in Creutzfeldt-Jakob disease cases or amyloid β plaques
in Alzheimer’s disease cases. In fact, cystatin F was barely detectable in patients with Creutz-
feldt-Jakob disease and Alzheimer’s disease, similarly to non-demented controls, whereas cysta-
tin F expression could be detected in inflammatory infiltrating cells in cases of meningitis.
It is also possible that prion-induced upregulation of Cst7 is a prion strain-dependent phe-
nomenon. This would not be unexpected, as prion strains transmit disease with distinctive
phenotypes, which include neuropathological and biochemical changes [1,4]. For example,
microglia activation, which plays a key neuroprotective role in prion diseases [46], was shown
to vary considerably among different prion models [47]. However, substantial upregulation of
Cst7 transcripts was detected in cultured murine microglia infected with the Creutzfeldt-Jakob
disease-derived Fukuoka strain [48], as well as in brains of mice infected with RML, ME7,
139A and 301V rodent-adapted scrapie prions [49–52]. Furthermore, we observed upregula-
tion of both Cst7 mRNA and cystatin F protein levels in brains of mice infected with RML and
22L prions.
These observations suggest that Cst7 upregulation is remarkably conserved upon exposure
to different prion strains, at least in mouse models of prion diseases. Whether Cst7 upregula-
tion occurs also in the context of field cases of animal prion disease has to be established. Of
interest are the results of a recent study testing levels of selected transcripts in two CNS areas
of a limited number of Creutzfeldt-Jakob disease cases, subtypes MM1 and VV2, and controls.
Compared to controls, a trend towards slightly increased CST7 levels was found in the frontal
cortex of patients with Creutzfeldt-Jakob disease subtype MM1, and in the cerebellum of
patients with Creutzfeldt-Jakob disease subtype VV2, yet none of these changes reached statis-
tical significance [53]. Conversely, there was a significant upregulation of microglial transcripts
CD68, ITGAM (encoding CD11b) and Aif1 (encoding Iba1) in frontal cortex of MM1 cases
and in cerebellum of VV2 cases [53]. This observation, together with the results of our studies,
suggests that the presence of microgliosis is not sufficient to cause a significant increase in
cystatin F levels in patients with Creutzfeldt-Jakob disease.
One possible explanation for the divergent observations in experimental and human prion
disease may lie in the intrinsic differences between mouse and human immune system, which
is shaped by a complex interplay of genetic, epigenetic and environmental factors, and exhibits
significant differences in development, homeostasis and response to challenge [54]. Multiple
divergent molecular pathways in immune cells have been described, including for macro-
phages [55] and microglia [56]. Also, transcriptional changes upon different pro-inflammatory
stimuli significantly diverge between mice and humans [57], and differences in selected
inflammatory molecules have been reported between brains of Creutzfeldt-Jakob disease
patients and brains of transgenic mice overexpressing the human prion protein and inoculated
with Creutzfeldt-Jakob disease-derived prions [53]. In this context, it is of interest to note that
Cst7 was among the most strongly upregulated transcripts in the hippocampus of young vs.
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old mice, ranking 2nd and 12th between 3 vs. 24 month-old mice and 3 vs. 29 month-old mice,
respectively [58]. Conversely, its human homologue CST7 was not differentially expressed in
the aging human brain (The Human Brain Transcriptome atlas [59]). Also, Cst7 transcripts
are almost exclusively found in microglia/macrophages in mouse brain, whereas CST7 tran-
scripts are present both in microglia/macrophages and endothelial cells in the human brain
[14,15].
The robust overexpression of Cst7/cystatin F in our investigated mouse models, together
with the upregulation of Serpina3n/α1-anti-chimotrypsin in both mouse models and human
cases of prion disease, suggests a role for cysteine protease inhibitors in prion pathogenesis.
Cysteine proteases have been found to be involved in the clearance of partially PK-resistant
PrP in vitro [60–62]. Also, upregulation of cysteine proteases has been reported in different cel-
lular and animal models of prion diseases [47,50,63–65] and in brains of Creutzfeldt-Jakob dis-
ease patients [66]. Further studies may clarify whether changes in cysteine proteases, and
inhibitors thereof, are directly involved in prion disease pathogenesis or instead represent
reactive changes.
As cystatin F can be secreted in the extracellular space and is present in body fluids, we
explored its potential as a biomarker of Creutzfeldt-Jakob disease, the prototypical prion dis-
ease in humans. However, we found no significant increase in cystatin F levels in either cere-
brospinal fluid or brain parenchyma of patients with Creutzfeldt-Jakob disease compared to
Alzheimer’s disease or non-demented controls. Our results demonstrate the existence of dra-
matic species differences between mice and humans in terms of brain cystatin F expression
during prion disease. They also rule out cystatin F as a useful surrogate biomarker in Creutz-
feldt-Jakob disease.
Supporting information
S1 Fig. Partially protease K-resistant PrP brain accumulation during prion disease. West-
ern blotting analysis showing the amount of partially protease K (PK)-resistant prion protein
(PrP) in whole-brain extracts of prion-infected mice at various dpi (upper membrane). Identi-
cal protein extracts omitting proteinase K treatment were used for western blotting with an
anti-actin antibody to allow for normalization and to verify equivalent loading in each lane
(lower membrane). Each lane denotes a brain extract from a representative mouse from each
group.
(TIF)
S2 Fig. Cst7 brain expression in physiologic and pathologic conditions. A Expression levels
of Cst7 in different cell types of the mouse brain based on RNA sequencing profiling of acutely
purified cell populations from the mouse brain cortex. FPKM: fragments per kilobase of tran-
script per million mapped reads. The oligodendrocyte precursor population is reported to
have a 5% contamination with microglia based on whole transcriptome profile. Dots: denote
individual cell preparations; bars: mean; error bars: standard deviation. Data are from the
mouse brain transcriptome database [14]. B Expression levels of CST7 in different cell types of
the human brain based on RNA sequencing profiling of acutely purified cell populations from
the human brain cortex. FPKM: fragments per kilobase of transcript per million mapped
reads. Dots: denote individual cell preparations; bars: mean; error bars: standard deviation.
Data are from the human brain transcriptome database [15]. C Expression levels of Cst7 in dif-
ferent developmental stages of mouse microglia and in relation to the expression of the early
microglial marker Tmem119 or to the treatment with lipopolysaccharide (LPS). En indicates
embryonal day n; Pn indicates post-natal day n. Dots: denote individual cell preparations;
bars: mean; error bars: standard deviation. Data are from the mouse developmental microglia
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dataset, Bennett et al. [16]. C Northern hybridization analysis of Cst7 mRNA in whole brains
of mice with different neurodegenerative/neuroinflammatory conditions, as compared with
levels in brains of mice at 190 days post injection (dpi) with RML prions or non-infectious
brain homogenate (NBH). ΔF: terminally sick mice expressing a toxic, truncated PrPC mole-
cule [31]; TgAPP23: aged mice overexpressing human APPSwe/V717I [32]; EAE: mice with
experimental autoimmune encephalitis induced by administration of MOG35-55 peptide emul-
sified in complete Freund’s adjuvant (CFA) and receiving an intraperitoneal injection with
pertussis toxin [11]; CFA: EAE control mice were only the injection of the MOG35-55 peptide
was omitted. Each lane denotes a pool of brain extracts from 3 mice.
(TIF)
S3 Fig. Cst7/cystatin F expression in different organs in mice. Correlation between cystatin
F protein levels (x axis) and Cst7 mRNA levels (y axis) in thymus and different regions of the
central nervous system (CNS) in adult C57BL/6J mice (n = 4 for all organs except n = 3 for spi-
nal cord). Each dot denotes an individual organ or CNS area. Inset: magnification of the area
delimited between the axis and the dashed lines.
(TIF)
S4 Fig. Cystatin F levels in cerebrospinal fluid from patients with different neurologic con-
ditions. Cystatin F levels were measured in patients with different neurological conditions
(Bact. Meningitis, bacterial meningitis; Vir. meningitis, viral meningitis). Dots: denote individ-
ual subjects; bars: mean; error bars: standard deviation (, p<0.05; , p<0.01, one-way
ANOVA followed by Bonferroni’s multiple comparison test).
(TIF)
S5 Fig. Microglia in brains from analyzed patients with Creutzfeldt-Jakob disease and Alz-
heimer’s disease. Histologic analysis of microglia (IBA1) in frontal cortex of the same cohort
of patients with Alzheimer’s disease (AD) and Creutzfeldt-Jakob disease (CJD) reported in Fig
5. Non-demented subjects were included as control (Ctrl). Images from two representative
cases per group are depicted. Scale bar: 100 μm.
(TIF)
S1 File. Uncropped and unmodified Western blot and Norther blot images.
(PDF)
S1 Table. Clinical assessment and scoring of wild-type mice inoculated with RML prions.
(DOCX)
S2 Table. Clinical assessment and scoring of wild-type mice after induction of experimen-
tal autoimmune encephalitis.
(DOCX)
S3 Table. List of primers used in this study.
(DOCX)
S4 Table. Differentially expressed probes as assessed by the perfect match-mismatch
model-based analysis of microarray data.
(XLSX)
S5 Table. Expression data (as reads per kilobase per million mapped reads, RPKM) of
Cst7, Gfap and Serpina3nduring prion disease as assessed by RNA sequencing.
(XLSX)
Cystatin F is a biomarker of prion pathogenesis in mice
PLOS ONE | DOI:10.1371/journal.pone.0171923 February 8, 2017 21 / 25
Acknowledgments
We thank B. Seifert for help with statistical analysis, Y. Zhang, S. Sloan, M. Bennett and B.A.
Barres for providing RNA sequencing data, P. Schwarz, M. Delic, K. Arroyo, B. Piccapietra, I.
Abakumova, M. Ko¨nig, G. Ilg-Frei and U. Wagner for excellent technical help and members of
the Aguzzi laboratory for critical discussions.
Author contributions
Conceptualization: MN GM AA.
Data curation: MN NS GM SS.
Formal analysis: MN NS GM ML EJR HB AA.
Funding acquisition: GM AA.
Investigation: MN NS GM SS R. Moos.
Project administration: MN ML R. Martin UK VK HB AA.
Resources: CS RRB MB PS KD IL.
Supervision: AA.
Visualization: MN NS GM AA.
Writing – original draft: MN NS GM AA.
Writing – review & editing: SS R. Moos SC RRB MB PS KD IL ML R. Martin UK VK EJR
HB.
References
1. Aguzzi A, Calella AM (2009) Prions: protein aggregation and infectious diseases. Physiol Rev 89:
1105–1152. doi: 10.1152/physrev.00006.2009 PMID: 19789378
2. Prusiner SB (1982) Novel proteinaceous infectious particles cause scrapie. Science 216: 136–144.
PMID: 6801762
3. Aguzzi A, Heikenwalder M, Polymenidou M (2007) Insights into prion strains and neurotoxicity. Nat Rev
Mol Cell Biol 8: 552–561. doi: 10.1038/nrm2204 PMID: 17585315
4. Aguzzi A, Nuvolone M, Zhu C (2013) The immunobiology of prion diseases. Nat Rev Immunol 13: 888–
902. doi: 10.1038/nri3553 PMID: 24189576
5. Zanusso G, Monaco S, Pocchiari M, Caughey B (2016) Advanced tests for early and accurate diagnosis
of Creutzfeldt-Jakob disease. Nat Rev Neurol 12: 325–333. doi: 10.1038/nrneurol.2016.65 PMID:
27174240
6. Miele G, Seeger H, Marino D, Eberhard R, Heikenwalder M, Stoeck K, et al. (2008) Urinary alpha1-
antichymotrypsin: a biomarker of prion infection. PLoS One 3: e3870. doi: 10.1371/journal.pone.
0003870 PMID: 19057641
7. Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW, et al. (2012) National Institute on
Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease:
a practical approach. Acta Neuropathol 123: 1–11. doi: 10.1007/s00401-011-0910-3 PMID: 22101365
8. Nuvolone M, Sorce S, Schwarz P, Aguzzi A (2015) Prion Pathogenesis in the Absence of NLRP3/ASC
Inflammasomes. PLoS One 10: e0117208. doi: 10.1371/journal.pone.0117208 PMID: 25671600
9. Zhu C, Schwarz P, Abakumova I, Aguzzi A (2015) Unaltered Prion Pathogenesis in a Mouse Model of
High-Fat Diet-Induced Insulin Resistance. PLoS One 10: e0144983. doi: 10.1371/journal.pone.
0144983 PMID: 26658276
10. Sorce S, Nuvolone M, Keller A, Falsig J, Varol A, Schwarz P, et al. (2014) The role of the NADPH oxi-
dase NOX2 in prion pathogenesis. PLoS Pathog 10: e1004531. doi: 10.1371/journal.ppat.1004531
PMID: 25502554
Cystatin F is a biomarker of prion pathogenesis in mice
PLOS ONE | DOI:10.1371/journal.pone.0171923 February 8, 2017 22 / 25
11. Becher B, Durell BG, Miga AV, Hickey WF, Noelle RJ (2001) The clinical course of experimental autoim-
mune encephalomyelitis and inflammation is controlled by the expression of CD40 within the central
nervous system. J Exp Med 193: 967–974. PMID: 11304557
12. Kosir R, Acimovic J, Golicnik M, Perse M, Majdic G, Fink M, et al. (2010) Determination of reference
genes for circadian studies in different tissues and mouse strains. BMC Mol Biol 11: 60. doi: 10.1186/
1471-2199-11-60 PMID: 20712867
13. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, et al. (2002) Accurate nor-
malization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control
genes. Genome Biol 3: RESEARCH0034. PMID: 12184808
14. Zhang Y, Chen K, Sloan SA, Bennett ML, Scholze AR, O’Keeffe S, et al. (2014) An RNA-sequencing
transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J Neu-
rosci 34: 11929–11947. doi: 10.1523/JNEUROSCI.1860-14.2014 PMID: 25186741
15. Zhang Y, Sloan SA, Clarke LE, Caneda C, Plaza CA, Blumenthal PD, et al. (2016) Purification and
Characterization of Progenitor and Mature Human Astrocytes Reveals Transcriptional and Functional
Differences with Mouse. Neuron 89: 37–53. doi: 10.1016/j.neuron.2015.11.013 PMID: 26687838
16. Bennett ML, Bennett FC, Liddelow SA, Ajami B, Zamanian JL, Fernhoff NB, et al. (2016) New tools for
studying microglia in the mouse and human CNS. Proc Natl Acad Sci U S A 113: E1738–1746. doi: 10.
1073/pnas.1525528113 PMID: 26884166
17. Nuvolone M, Kana V, Hutter G, Sakata D, Mortin-Toth SM, Russo G, et al. (2013) SIRPalpha polymor-
phisms, but not the prion protein, control phagocytosis of apoptotic cells. J Exp Med 210: 2539–2552.
doi: 10.1084/jem.20131274 PMID: 24145514
18. Nuvolone M, Hermann M, Sorce S, Russo G, Tiberi C, Schwarz P, et al. (2016) Strictly co-isogenic
C57BL/6J-Prnp-/- mice: A rigorous resource for prion science. J Exp Med 213: 313–327. doi: 10.1084/
jem.20151610 PMID: 26926995
19. Beerli RR, Bauer M, Buser RB, Gwerder M, Muntwiler S, Maurer P, et al. (2008) Isolation of human
monoclonal antibodies by mammalian cell display. Proc Natl Acad Sci U S A 105: 14336–14341. doi:
10.1073/pnas.0805942105 PMID: 18812621
20. Koller D, Ruedl C, Loetscher M, Vlach J, Oehen S, Oertle K, et al. (2001) A high-throughput alphavirus-
based expression cloning system for mammalian cells. Nat Biotechnol 19: 851–855. doi: 10.1038/
nbt0901-851 PMID: 11533644
21. Polymenidou M, Moos R, Scott M, Sigurdson C, Shi YZ, Yajima B, et al. (2008) The POM monoclonals:
a comprehensive set of antibodies to non-overlapping prion protein epitopes. PLoS One 3: e3872. doi:
10.1371/journal.pone.0003872 PMID: 19060956
22. Beasley TM, Holt JK, Allison DB (2005) Comparison of linear weighting schemes for perfect match and
mismatch gene expression levels from microarray data. Am J Pharmacogenomics 5: 197–205. PMID:
15952873
23. Schinke-Braun M, Couget JA (2007) Expression profiling using affymetrix genechip probe arrays. Meth-
ods Mol Biol 366: 13–40. doi: 10.1007/978-1-59745-030-0_2 PMID: 17568117
24. Ni J, Fernandez MA, Danielsson L, Chillakuru RA, Zhang J, Grubb A, et al. (1998) Cystatin F Is a Glyco-
sylated Human Low Molecular Weight Cysteine Proteinase Inhibitor. Journal of Biological Chemistry
273: 24797–24804. PMID: 9733783
25. Halfon S, Ford J, Foster J, Dowling L, Lucian L, Sterling M, et al. (1998) Leukocystatin, A New Class II
Cystatin Expressed Selectively by Hematopoietic Cells. Journal of Biological Chemistry 273: 16400–
16408. PMID: 9632704
26. Morita M, Hara Y, Tamai Y, Arakawa H, Nishimura S (2000) Genomic construct and mapping of the
gene for CMAP (leukocystatin/cystatin F, CST7) and identification of a proximal novel gene, BSCv
(C20orf3). Genomics 67: 87–91. doi: 10.1006/geno.2000.6237 PMID: 10945474
27. Hamilton G, Colbert JD, Schuettelkopf AW, Watts C (2008) Cystatin F is a cathepsin C-directed prote-
ase inhibitor regulated by proteolysis. EMBO J 27: 499–508. doi: 10.1038/sj.emboj.7601979 PMID:
18256700
28. Matthews SP, McMillan SJ, Colbert JD, Lawrence RA, Watts C (2016) Cystatin F Ensures Eosinophil
Survival by Regulating Granule Biogenesis. Immunity 44: 795–806. doi: 10.1016/j.immuni.2016.03.003
PMID: 27067058
29. Ma J, Tanaka KF, Shimizu T, Bernard CC, Kakita A, Takahashi H, et al. (2011) Microglial cystatin F
expression is a sensitive indicator for ongoing demyelination with concurrent remyelination. J Neurosci
Res 89: 639–649. doi: 10.1002/jnr.22567 PMID: 21344476
30. Duan W, Ran H, Zhou Z, He Q, Zheng J (2012) Adenosine A2A receptor deficiency up-regulates cysta-
tin F expression in white matter lesions induced by chronic cerebral hypoperfusion. PLoS One 7:
e52566. doi: 10.1371/journal.pone.0052566 PMID: 23285090
Cystatin F is a biomarker of prion pathogenesis in mice
PLOS ONE | DOI:10.1371/journal.pone.0171923 February 8, 2017 23 / 25
31. Shmerling D, Hegyi I, Fischer M, Blattler T, Brandner S, Gotz J, et al. (1998) Expression of amino-termi-
nally truncated PrP in the mouse leading to ataxia and specific cerebellar lesions. Cell 93: 203–214.
PMID: 9568713
32. Sturchler-Pierrat C, Abramowski D, Duke M, Wiederhold KH, Mistl C, Rothacher S, et al. (1997) Two
amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl
Acad Sci U S A 94: 13287–13292. PMID: 9371838
33. Stoeck K, Sanchez-Juan P, Gawinecka J, Green A, Ladogana A, Pocchiari M, et al. (2012) Cerebrospi-
nal fluid biomarker supported diagnosis of Creutzfeldt-Jakob disease and rapid dementias: a longitudi-
nal multicentre study over 10 years. Brain 135: 3051–3061. doi: 10.1093/brain/aws238 PMID:
23012332
34. Chong MS, Sahadevan S (2005) Preclinical Alzheimer’s disease: diagnosis and prediction of progres-
sion. Lancet Neurol 4: 576–579. doi: 10.1016/S1474-4422(05)70168-X PMID: 16109364
35. Parchi P, Castellani R, Capellari S, Ghetti B, Young K, Chen SG, et al. (1996) Molecular basis of pheno-
typic variability in sporadic Creutzfeldt-Jakob disease. Ann Neurol 39: 767–778. doi: 10.1002/ana.
410390613 PMID: 8651649
36. Parchi P, de Boni L, Saverioni D, Cohen ML, Ferrer I, Gambetti P, et al. (2012) Consensus classification
of human prion disease histotypes allows reliable identification of molecular subtypes: an inter-rater
study among surveillance centres in Europe and USA. Acta Neuropathol 124: 517–529. doi: 10.1007/
s00401-012-1002-8 PMID: 22744790
37. Parchi P, Saverioni D (2012) Molecular pathology, classification, and diagnosis of sporadic human
prion disease variants. Folia Neuropathol 50: 20–45. PMID: 22505361
38. Kim KS (2003) Pathogenesis of bacterial meningitis: from bacteraemia to neuronal injury. Nat Rev Neu-
rosci 4: 376–385. doi: 10.1038/nrn1103 PMID: 12728265
39. Weiss N, Miller F, Cazaubon S, Couraud PO (2009) The blood-brain barrier in brain homeostasis and
neurological diseases. Biochim Biophys Acta 1788: 842–857. doi: 10.1016/j.bbamem.2008.10.022
PMID: 19061857
40. Teunissen CE, Tumani H, Engelborghs S, Mollenhauer B (2014) Biobanking of CSF: international stan-
dardization to optimize biomarker development. Clin Biochem 47: 288–292. doi: 10.1016/j.clinbiochem.
2013.12.024 PMID: 24389077
41. Janowski R, Kozak M, Jankowska E, Grzonka Z, Grubb A, Abrahamson M, et al. (2001) Human cystatin
C, an amyloidogenic protein, dimerizes through three-dimensional domain swapping. Nat Struct Biol 8:
316–320. doi: 10.1038/86188 PMID: 11276250
42. Levy E, Lopez-Otin C, Ghiso J, Geltner D, Frangione B (1989) Stroke in Icelandic patients with heredi-
tary amyloid angiopathy is related to a mutation in the cystatin C gene, an inhibitor of cysteine prote-
ases. J Exp Med 169: 1771–1778. PMID: 2541223
43. Palsdottir A, Abrahamson M, Thorsteinsson L, Arnason A, Olafsson I, Grubb A, et al. (1988) Mutation in
cystatin C gene causes hereditary brain haemorrhage. Lancet 2: 603–604. PMID: 2900981
44. Sastre M, Calero M, Pawlik M, Mathews PM, Kumar A, Danilov V, et al. (2004) Binding of cystatin C to
Alzheimer’s amyloid beta inhibits in vitro amyloid fibril formation. Neurobiol Aging 25: 1033–1043. doi:
10.1016/j.neurobiolaging.2003.11.006 PMID: 15212828
45. Mi W, Pawlik M, Sastre M, Jung SS, Radvinsky DS, Klein AM, et al. (2007) Cystatin C inhibits amyloid-
beta deposition in Alzheimer’s disease mouse models. Nat Genet 39: 1440–1442. doi: 10.1038/ng.
2007.29 PMID: 18026100
46. Zhu C, Herrmann US, Falsig J, Abakumova I, Nuvolone M, Schwarz P, et al. (2016) A neuroprotective
role for microglia in prion diseases. J Exp Med 213: 1047–1059. doi: 10.1084/jem.20151000 PMID:
27185853
47. Baker CA, Lu ZY, Zaitsev I, Manuelidis L (1999) Microglial activation varies in different models of
Creutzfeldt-Jakob disease. J Virol 73: 5089–5097. PMID: 10233972
48. Baker CA, Manuelidis L (2003) Unique inflammatory RNA profiles of microglia in Creutzfeldt-Jakob dis-
ease. Proc Natl Acad Sci U S A 100: 675–679. doi: 10.1073/pnas.0237313100 PMID: 12525699
49. Riemer C, Neidhold S, Burwinkel M, Schwarz A, Schultz J, Kratzschmar J, et al. (2004) Gene expres-
sion profiling of scrapie-infected brain tissue. Biochem Biophys Res Commun 323: 556–564. doi: 10.
1016/j.bbrc.2004.08.124 PMID: 15369787
50. Xiang W, Windl O, Wunsch G, Dugas M, Kohlmann A, Dierkes N, et al. (2004) Identification of differen-
tially expressed genes in scrapie-infected mouse brains by using global gene expression technology. J
Virol 78: 11051–11060. doi: 10.1128/JVI.78.20.11051-11060.2004 PMID: 15452225
51. Xiang W, Hummel M, Mitteregger G, Pace C, Windl O, Mansmann U, et al. (2007) Transcriptome analy-
sis reveals altered cholesterol metabolism during the neurodegeneration in mouse scrapie model. J
Neurochem 102: 834–847. doi: 10.1111/j.1471-4159.2007.04566.x PMID: 17437544
Cystatin F is a biomarker of prion pathogenesis in mice
PLOS ONE | DOI:10.1371/journal.pone.0171923 February 8, 2017 24 / 25
52. Hwang D, Lee IY, Yoo H, Gehlenborg N, Cho JH, Petritis B, et al. (2009) A systems approach to prion
disease. Mol Syst Biol 5: 252. doi: 10.1038/msb.2009.10 PMID: 19308092
53. Llorens F, Lopez-Gonzalez I, Thune K, Carmona M, Zafar S, Andreoletti O, et al. (2014) Subtype and
regional-specific neuroinflammation in sporadic creutzfeldt-jakob disease. Front Aging Neurosci 6:
198. doi: 10.3389/fnagi.2014.00198 PMID: 25136317
54. Mestas J, Hughes CC (2004) Of mice and not men: differences between mouse and human immunol-
ogy. J Immunol 172: 2731–2738. PMID: 14978070
55. Schneemann M, Schoedon G (2002) Species differences in macrophage NO production are important.
Nat Immunol 3: 102. doi: 10.1038/ni0202-102a PMID: 11812978
56. Smith AM, Dragunow M (2014) The human side of microglia. Trends Neurosci 37: 125–135. doi: 10.
1016/j.tins.2013.12.001 PMID: 24388427
57. Seok J, Warren HS, Cuenca AG, Mindrinos MN, Baker HV, Xu W, et al. (2013) Genomic responses in
mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci U S A 110: 3507–3512.
doi: 10.1073/pnas.1222878110 PMID: 23401516
58. Stilling RM, Benito E, Gertig M, Barth J, Capece V, Burkhardt S, et al. (2014) De-regulation of gene
expression and alternative splicing affects distinct cellular pathways in the aging hippocampus. Front
Cell Neurosci 8: 373. doi: 10.3389/fncel.2014.00373 PMID: 25431548
59. Lu T, Pan Y, Kao SY, Li C, Kohane I, Chan J, et al. (2004) Gene regulation and DNA damage in the age-
ing human brain. Nature 429: 883–891. doi: 10.1038/nature02661 PMID: 15190254
60. Luhr KM, Nordstro¨m EK, Lo¨w P, Kristensson K (2004) Cathepsin B and L are involved in degradation of
prions in GT1-1 neuronal cells. NeuroReport 15: 1663–1667. PMID: 15232303
61. Luhr KM, Nordstrom EK, Low P, Ljunggren HG, Taraboulos A, Kristensson K (2004) Scrapie Protein
Degradation by Cysteine Proteases in CD11c+ Dendritic Cells and GT1-1 Neuronal Cells. Journal of
Virology 78: 4776–4782. doi: 10.1128/JVI.78.9.4776-4782.2004 PMID: 15078959
62. Doh-Ura K, Iwaki T, Caughey B (2000) Lysosomotropic agents and cysteine protease inhibitors inhibit
scrapie-associated prion protein accumulation. J Virol 74: 4894–4897. PMID: 10775631
63. Diedrich JF, Minnigan H, Carp RI, Whitaker JN, Race R, Frey W 2nd, et al. (1991) Neuropathological
changes in scrapie and Alzheimer’s disease are associated with increased expression of apolipoprotein
E and cathepsin D in astrocytes. J Virol 65: 4759–4768. PMID: 1870200
64. Zhang Y, Spiess E, Groschup MH, Burkle A (2003) Up-regulation of cathepsin B and cathepsin L activi-
ties in scrapie-infected mouse Neuro2a cells. J Gen Virol 84: 2279–2283. doi: 10.1099/vir.0.19153-0
PMID: 12867662
65. Vidal E, Tortosa R, Marco P, Fondevila D, Rabanal RM, Torres JM, et al. (2013) Late stage cathepsin
C, CXCL13 and Ki-67 overexpression correlate with regional neuropathology in a BSE transgenic
murine model. J Comp Pathol 148: 22–32. doi: 10.1016/j.jcpa.2012.05.004 PMID: 22789860
66. Kovacs GG, Gelpi E, Strobel T, Ricken G, Nyengaard JR, Bernheimer H, et al. (2007) Involvement of
the endosomal-lysosomal system correlates with regional pathology in Creutzfeldt-Jakob disease. J
Neuropathol Exp Neurol 66: 628–636. doi: 10.1097/nen.0b013e318093ecc7 PMID: 17620988
Cystatin F is a biomarker of prion pathogenesis in mice
PLOS ONE | DOI:10.1371/journal.pone.0171923 February 8, 2017 25 / 25
